Nature - USA (2020-08-20)

4

nature research | reporting summary

October 2018

Human research participants

Policy information about studies involving human research participants

Population characteristics We studied 4 subjects with previous laboratory-confirmed symptomatic SARS-CoV-2 infection that was acquired in China, and

one healthy control subject:

Subject 1: Male, 35 years old

Subject 2: Female, 52 years old

Subject 3: Male, 56 years old

Subject 4: Female, 56 years old

Healthy control subject:

Subject 5, Male, 58 years old

Two subjects from which mAbs were isolated (the 56-year-old male and a 56-year-old female) are a married couple and

residents of Wuhan, China, who traveled to Toronto, Canada and were diagnosed with SARS-CoV-2 infection by RT-PCR as

described previously (PMID: 32511414). Male subject developed symptoms suggestive of COVID-19 and female subject was

asymptomatic when RT-PCR tested. At the time of PBMCs collection, male subject was free of symptoms suggestive of COVID-19

for at least 14 days and both subjects had negative nasopharyngeal swab RT-PCR tests. These samples were transferred to

Vanderbilt University Medical Center in Nashville, TN, USA on March 14, 2020.

Recruitment Study participants were recruited at the hospital in Toronto, and PBMCs were obtained by leukapheresis on March 10, 2020,

which is 50 days after symptom onset for the male subject and 18 days after negative RT-PCR test for the female subject. These

two subjects were selected on the basis of high SARS-CoV-2-specific B cell frequency in these samples with the aim to facilitate

identification of potent monoclonal antibodies, as described previously (PMID: 32511414). Samples were obtained after written

informed consent. There was no potential self-selection bias in recruiting patients.

Ethics oversight Ethics oversight

Studies to obtain specimens after written informed consent had been approved by the Institutional Review Board of Vanderbilt

University Medical Center, the Institutional Review Board of the University of Washington, and the Research Ethics Board of the

University of Toronto.

Note that full information on the approval of the study protocol must also be provided in the manuscript.